nifedipine

(redirected from Adalat cc)
Also found in: Dictionary, Thesaurus.

nifedipine

 [ni-fed´ĭ-pēn]
a calcium channel blocking agent administered orally as a coronary vasodilator in the treatment of angina pectoris; also used in the treatment of hypertension.

nifedipine

/ni·fed·i·pine/ (ni-fed´ĭ-pēn) a calcium channel blocking agent used as a coronary vasodilator in the treatment of coronary insufficiency and angina pectoris; also used in the treatment of hypertension.

nifedipine

(nī-fĕd′ə-pēn′)
n.
A calcium channel blocker drug, C17H18N2O6, that acts as a coronary vasodilator and is used primarily to treat hypertension and angina pectoris.

NIFEdipine

[nifed′ipēn]
a calcium channel blocker.
indications It is prescribed for the treatment of vasospastic and effort-associated angina, pulmonary hypertension, and hypertension (sustained-release form only).
contraindications Known hypersensitivity to this drug prohibits its use, and immediate-release forms should not be used to treat hypertension. The practice of using short-acting sublingual nifedipine in hypertensive emergencies or pseudoemergencies is dangerous and should be abandoned.
adverse effects Among the more serious adverse effects are hypotension, peripheral edema, palpitations, dyspnea, nausea, dizziness, flushing, and headache. When given sublingually, stroke, severe hypotension, syncope, heart block, sinus arrest, myocardial infarctions, and fetal distress are among the adverse effects reported.

nifedipine

Procardia® Cardiology A dihydropiridine CCB vasodilator used for angina, as a short-acting antihypertensive–↓ BP, resulting in a ↓ left ventricular volume and myocardial mass, ↑ ejection fraction Side effects Tachycardia, headache, peripheral edema, cerebral ischemia, stroke, severe hypotension, AMI, conduction defects, fetal distress, death. See Calcium channel blockers, Hypertension, TIBBS.

nifedipine

A CALCIUM CHANNEL BLOCKER drug used to control the symptoms of ANGINA PECTORIS and to treat high blood pressure (HYPERTENSION). It has a powerful effect in widening (dilating) arteries, including the coronary arteries, and this improves the blood supply to the heart muscle. The drug, however, causes flushing, headache, skin itching and dizziness. It is often used in combination with a BETA-BLOCKER. Nifedipine has been used effectively to prevent high altitude lung oedema, a feature of mountain sickness. The drug is on the WHO official list. Brand names are Adalat, Adipine MR, Angiopine MR, Cardilate MR, Coracten, Fortipine LA, Tensipine MR and Unipine XL.

nifedipine

calcium channel-blocking drug; may be used to treat severe perniosis, or to control pain of leiomyoma

nifedipine (nīfed´əpēn´),

n brand names: Procardia, Procardia XL;
drug class: calcium channel blocker;
action: inhibits calcium ion influx across cell membrane during cardiac depolarization; produces relaxation of coronary vascular smooth muscle, dilates coronary arteries; increases myocardial oxygen delivery in patients with vasospastic angina; dilates peripheral arteries;
uses: chronic stable angina pectoris, vasospastic angina, hypertension. Can cause gingival hyperplasia.

nifedipine

a calcium channel blocker used principally as a vasodilator.
References in periodicals archive ?
Thus Elan's nifedipine 60 mg will be the second generic copy of Bayer's Adalat CC 60 mg on the market.
Biovail's introduction of generic Adalat CC represents its third product launch in three months and its fifth debut of a generic version of a controlled-release product.
Biovail, through its marketing partner Teva Pharmaceuticals, is currently marketing generic versions of Adalat CC (30mg and 60mg) and Procardia XL (60mg) dosage strengths.
We continue to believe that patients find it useful to learn from their pharmacists about such new, safe and less expensive products as Adalat CC," says a Miles spokesman.
The 30mg dosage strength represents approximately 35% of total Adalat CC brand sales.
The launch of generic Adalat CC represents Biovail's third product launch in less than three months and Biovail's fifth launch of a generic version of a controlled release product.
Adalat CC is indicated for the treatment of hypertension and is marketed by Bayer Corporation.
Biovail was the first company to file an abbreviated new drug application ("ANDA") with the FDA for the 60mg strength of Adalat CC and will be entitled to 180 days of marketing exclusivity.
Upon introduction, Biovail's generic version of Adalat CC will be marketed in the US by Teva Pharmaceuticals USA Inc.
The approval of our first Abbreviated New Drug Application for pentoxifylline and significant product filings with the Food and Drug Administration including generic versions of Procardia XL, Adalat CC, Voltaren XR and Dilacor XR during 1998, confirms the Company's ability to meet strategic objectives and will allow the Company to significantly build upon our existing business.
Biovail has an additional five ANDA applications including generic versions of Cardizem CD, Cardizem SR, Verelan, Procardia XL and Adalat CC, awaiting FDA approval.
We have had a very exciting and rewarding year in which record profits were earned, additional international licensing agreements for Tiazac(R) were finalized; regulatory approval for the sale of Tiazac(R) in Canada was received; scientific milestones were achieved with the ANDA filing of major products with the FDA, including Cardizem CD, Verelan and recently Adalat CC and Procardia XL; and the licensing of certain of the Company's ANDA pipeline in Canada.